Peking University Stem Cell Research Center, Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
PLoS One. 2012;7(10):e46934. doi: 10.1371/journal.pone.0046934. Epub 2012 Oct 9.
Heterozygous paired box6 (Pax6) mutations lead to abnormal glucose metabolism in mice older than 6 months as well as in human beings. Our previous study found that Pax6 deficiency caused down-expression of prohormone convertase 1/3 (Pcsk1), resulting in defective proinsulin processing. As a protein cleaving enzyme, in addition to its expression, the activity of PC1/3 is closely related to its function. We therefore hypothesize that Pax6 mutation alters the activity of PC1/3, which affects proinsulin processing.
METHODOLOGY/PRINCIPAL FINDINGS: Using quantitative RT-PCR, western blot and enzyme assay, we found that PC1/3 C-terminal cleavage and its activity were compromised in Pax6 R266Stop mutant mice, and the expression of Pcsk1n, a potent inhibitor of PC1/3, was elevated by Pax6 deficiency in the mutant mice and MIN6 cells. We confirmed the effect of proSAAS, the protein encoded by Pcsk1n, on PC1/3 C-terminal cleavage and its activity by Pcsk1n RNAi in MIN6 cells. Furthermore, by luciferase-reporter analysis, chromatin immunoprecipitation, and electrophoretic mobility shift assay, we revealed that Pax6 bound to Pcsk1n promoter and directly down-regulated its expression. Finally, by co-transfecting Pax6 siRNA with Pcsk1n siRNA, we showed that Pax6 knock-down inhibited proinsulin processing and that this effect could be rescued by proSAAS down-regulation. These findings confirm that Pax6 regulates proinsulin processing partially through proSAAS-mediated PC1/3 processing and activity.
CONCLUSIONS/SIGNIFICANCE: Collectively, the above experiments demonstrate that Pax6 can directly down-regulate Pcsk1n expression, which negatively affects PC1/3 C-terminal cleavage and activity and subsequently participates in proinsulin processing. We identified proSAAS as a novel down-regulated target of Pax6 in the regulation of glucose metabolism. This study also provides a complete molecular mechanism for the Pax6 deficiency-caused diabetes.
杂合性配对盒 6(Pax6)突变导致 6 个月以上的小鼠和人类的葡萄糖代谢异常。我们之前的研究发现,Pax6 缺失导致前激素转化酶 1/3(Pcsk1)的表达下调,导致胰岛素原处理缺陷。作为一种蛋白裂解酶,除了其表达外,PC1/3 的活性与其功能密切相关。因此,我们假设 Pax6 突变改变了 PC1/3 的活性,从而影响了胰岛素原的处理。
方法/主要发现:使用定量 RT-PCR、western blot 和酶活性测定,我们发现 Pax6 R266Stop 突变小鼠中 PC1/3 C 端切割及其活性受损,且 Pax6 缺失导致突变小鼠和 MIN6 细胞中 Pcsk1n 的表达升高,Pcsk1n 是 PC1/3 的一种强有力的抑制剂。我们通过 MIN6 细胞中的 Pcsk1n RNAi 证实了 proSAAS,即 Pcsk1n 编码的蛋白,对 PC1/3 C 端切割及其活性的影响。此外,通过荧光素酶报告分析、染色质免疫沉淀和电泳迁移率变动分析,我们揭示了 Pax6 结合到 Pcsk1n 启动子上并直接下调其表达。最后,通过共转染 Pax6 siRNA 和 Pcsk1n siRNA,我们表明 Pax6 敲低抑制了胰岛素原的处理,而这种作用可以通过下调 proSAAS 来挽救。这些发现证实,Pax6 通过 proSAAS 介导的 PC1/3 处理和活性部分调节胰岛素原的处理。
结论/意义:总之,上述实验表明 Pax6 可以直接下调 Pcsk1n 的表达,这反过来又影响了 PC1/3 C 端切割和活性,随后参与了胰岛素原的处理。我们发现 proSAAS 是 Pax6 在葡萄糖代谢调节中下调的一个新的靶标。该研究还为 Pax6 缺乏引起的糖尿病提供了一个完整的分子机制。